The Alfred E. Mann Institute for Biomedical Engineering at USC (AMI-USC) was founded in 1998 with the mission of accelerating the commercialization of biomedical technology invented at USC. For development of its biomedical technology, AMI-USC partners with researchers throughout the university, where it is developed to a mature stage, validated, patented, and can be licensed to an industry partner or used for the formation of a start-up company along with external investment.
The AMI-USC team is comprised of engineers, scientists, patent attorneys, regulatory experts, and business development professionals. The team is dedicated to focusing on complicated details of creating new products. The Institute helps tackle the more difficult parts of bringing medical inventions to the market such as developing intellectual property and regulatory strategies. The Institute practices “parallel processing,” a way to accelerate the legal processes, business development, and the science at the same time. The Institute also aids researchers in testing, scaling, product design, and marketing. The Institute has been instrumental in developing a number of medical products and start-up companies.
About the Founder
Mr. Alfred E. Mann (1925-2016), through his creation of the Alfred Mann Foundation and 17 other companies that he supported throughout his life, took on big healthcare problems and met them with bold, innovative solutions. His legacy includes rechargeable pacemakers, insulin pumps, cochlear implants, artificial retinas, mind-controlled prosthetic limbs, inhalable insulin, and microstimulators that alleviate pain and restore lost limb function. As he advanced the science of medical devices to new levels, his pioneering vision in the treatment of serious and debilitating conditions has helped countless millions of people improve their quality of life.